Medical AI startup OpenEvidence doubles valuation to $12 billion in latest round
OpenEvidence's ad-supported AI chatbot for doctors reached $100 million annual revenue and 18 million clinical consultations in December, led by Thrive Capital and DST.
- On Jan 21, 2026, OpenEvidence closed a $250 million Series D at a $12 billion valuation, co-led by Thrive Capital and DST Global.
- To scale product specialization, OpenEvidence plans to build an orchestra of smaller specialist medical models focusing on oncology, radiology, and neurology, while monetizing its advertising revenue model after crossing $100 million annually.
- Clinician adoption has grown rapidly, with about 740,000 physicians—about 45% of doctors in the United States—using the platform and supporting 18 million clinical consultations last month.
- The company says its recent fundraising brings total capital raised to roughly the high hundreds of millions, with Daniel Nadler's net worth doubling to $7.6 billion and Zachary Ziegler holding a 7.3% stake worth $875 million.
- The financing positions OpenEvidence to accelerate specialist models in a $5 trillion U.S. health-care market, with Nadler saying real-world clinical consultations serve as a key moat amid competition from OpenAI and Anthropic.
14 Articles
14 Articles
Medical AI startup OpenEvidence doubles valuation to $12 billion in latest round
OpenEvidence, an AI startup whose tools are used by U.S. physicians, has raised $250 million in fresh funding at a $12 billion valuation, the Nvidia and Google Ventures-backed company said on Wednesday, doubling its value in just three months.
AI startup known as ‘ChatGPT for doctors’ doubles valuation to $12B in latest funding round
OpenEvidence, an artificial intelligence startup known as “ChatGPT for doctors,” clinched a funding round that doubled its valuation to a staggering $12 billion, the company told The Post.
OpenEvidence, the ‘ChatGPT for Doctors’ AI startup, hits $12B valuation in $250M Thrive-led round - Tech Startups
OpenEvidence just pulled off one of the fastest valuation climbs in healthcare AI. The Miami-based startup, often described as “ChatGPT for doctors,” closed a $250 million funding round led by Thrive Capital and DST, valuing it at $12 billion, the […] The post OpenEvidence, the ‘ChatGPT for Doctors’ AI startup, hits $12B valuation in $250M Thrive-led round first appeared on Tech Startups.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
